New CXCR4 Antagonist Peptide R (Pep R) Improves Standard Therapy in Colorectal Cancer

The chemokine receptor CXCR4 is overexpressed and functional in colorectal cancer. To investigate the role of CXCR4 antagonism in potentiating colon cancer standard therapy, the new peptide CXCR4 antagonist Peptide R (Pep R) was employed. Human colon cancer HCT116 xenograft-bearing mice were treated...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Crescenzo D’Alterio, Antonella Zannetti, Anna Maria Trotta, Caterina Ieranò, Maria Napolitano, Giuseppina Rea, Adelaide Greco, Piera Maiolino, Sandra Albanese, Giosuè Scognamiglio, Fabiana Tatangelo, Salvatore Tafuto, Luigi Portella, Sara Santagata, Guglielmo Nasti, Alessandro Ottaiano, Roberto Pacelli, Paolo Delrio, Gerardo Botti, Stefania Scala
Format: Artigo
Langue:Inglês
Publié: MDPI AG 2020-07-01
Collection:Cancers
Sujets:
colorectal cancer
CXCR4/CXCL12 axis
EMT epithelial-to-mesenchymal transition
radiotherapy
chemotherapy
chemoresistance
Accès en ligne:https://www.mdpi.com/2072-6694/12/7/1952
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires